VKORC1 encodes an enzyme that recycles vitamin K, which is crucial for activating clotting factors and bone proteins like osteocalcin. During menopause, declining estrogen accelerates bone loss. Vitamin K-dependent proteins may theoretically slow this process, but evidence for a clinically relevant role of VKORC1 variants in menopause is weak. Some GWAS have linked VKORC1 SNPs to bone mineral density, but effect sizes are small and insufficient for personalized recommendations. Moreover, VKORC1 is primarily known for its role in warfarin dosing. Genetic testing for VKORC1 in the context of menopause is not clinically validated and should not be used alone to guide diet or supplementation. Calcium, vitamin D, and exercise have far greater impact on bone health during menopause.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-2f4b51c6889cf074efee429c